CMV-SPECIFIC CELLULAR IMMUNITY IN RECIPIENTS OF ALLOGENIC BONE MARROW TRANSPLANT

同种异体骨髓移植受者的 CMV 特异性细胞免疫

• 批准号: 7368155
• 负责人: John A Zaia
• 金额: $ 17.2万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7368155
• 关键词: CMV; SPECIFIC; CELLULAR; IMMUNITY; RECIPIENTS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine whether an experimental test for immunity to CMV can determine when immunity to this virus is present after transplantation and whether the test can predict that a person is protected from serious CMV infections after transplantation. Participation in this study is expected to last approximately 5 days for donors, and for 1 year for transplant recipients. An ability to protect yourself from CMV infection is called CMV-specific cellular immunity. This immunity is among the most important factors that determine whether you will get a serious CMV infection after transplantation. There are various ways to measure this immunity. One of the most important ways is to determine if your lymphocytes (cell immunity) can kill CMV-infected cells. This is called a CTL assay. It is known that persons who develop good CTL levels have protection against severe CMV infection after transplantation. The CTL test is difficult to perform and an experimental test has been developed to try to predict whether or not a person is immune. This experimental test is called the HLA-peptide tetramer binding assay (TBA), and, although it is known that the TBA works well in the test tube, it has not yet been evaluated in persons undergoing transplantation. The goals of this study are to determine how best to perform the TBA test for transplant patients and to determine whether or not your TBA levels predict whether you will be protected from CMV infection or disease after transplant. Another goal of this study will be to determine what effects your treatments have on your levels of CMV immunity as measured by this experimental test and other tests of immunity.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究的目的是确定对巨细胞病毒免疫的实验测试是否可以确定移植后对该病毒的免疫是否存在，以及该测试是否可以预测移植后一个人免受严重巨细胞病毒感染。对于供体，参与这项研究预计持续约5天，对于移植受体，参与时间为1年。保护自己免受巨细胞病毒感染的能力被称为巨细胞病毒特异性细胞免疫。这种免疫力是决定移植后是否会发生严重巨细胞病毒感染的最重要因素之一。有多种方法可以测量这种免疫力。最重要的方法之一是确定你的淋巴细胞（细胞免疫）是否能杀死cmv感染的细胞。这被称为CTL试验。众所周知，培养出良好CTL水平的人在移植后对严重的巨细胞病毒感染具有保护作用。CTL测试很难进行，已经开发出一种实验性测试，试图预测一个人是否具有免疫力。这种实验试验被称为hla -肽四聚体结合试验（TBA），尽管已知TBA在试管中效果良好，但尚未在接受移植的人身上进行评估。本研究的目的是确定如何最好地对移植患者进行TBA检测，并确定TBA水平是否能预测移植后患者是否会受到CMV感染或疾病的保护。这项研究的另一个目标是确定你的治疗对你的巨细胞病毒免疫水平有什么影响，通过这个实验测试和其他免疫测试来测量。